{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:43:16Z","timestamp":1747183396711,"version":"3.40.5"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>This study aimed to evaluate the impact of the risk minimisation measures issued by the European Medicines Agency in 2014 to restrict the combined use of renin\u2013angiotensin system (RAS) blocking agents in Denmark. Data from the Danish National Prescription Registry covering all medications dispensed during January 2008\u2013December 2018 was used. The outcome was monthly prevalence of patients codispensed RAS blockers. Autoregressive integrated moving average interrupted time series regression was used to evaluate dispensing trends. The prevalence of patients codispensed RAS blockers decreased from 0.01 to 0.0003%. Preintervention trend was declining and further decreased with an additional \u22120.45 (95% confidence interval \u22120.66, \u22120.25) codispensing per million population after the intervention. Overall, the intervention had minimal impact on the combined use of RAS blockers. However, as the combined use of RAS blockers is low, further interventions to restrict the combined use of RAS blockers may not be required in Denmark at this point.<\/jats:p>","DOI":"10.1111\/bcp.15080","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T01:38:48Z","timestamp":1631583528000},"page":"1379-1384","source":"Crossref","is-referenced-by-count":1,"title":["Impact of regulatory interventions to restrict the combined use of renin\u2013angiotensin system blockers: A Danish nationwide drug utilisation study"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-6330","authenticated-orcid":false,"given":"Per","family":"Sindahl","sequence":"first","affiliation":[{"name":"Division of Pharmacovigilance and Medical Devices Danish Medicines Agency  Copenhagen Denmark"},{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science Utrecht University  Utrecht The Netherlands"},{"name":"Copenhagen Centre for Regulatory Science, Department of Pharmacy, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ofori\u2010Asenso","sequence":"additional","affiliation":[{"name":"Copenhagen Centre for Regulatory Science, Department of Pharmacy, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine Erikstrup","family":"Hallgreen","sequence":"additional","affiliation":[{"name":"Copenhagen Centre for Regulatory Science, Department of Pharmacy, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaare","family":"Kemp","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance and Medical Devices Danish Medicines Agency  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-9684","authenticated-orcid":false,"given":"Helga","family":"Gardarsdottir","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science Utrecht University  Utrecht The Netherlands"},{"name":"Department of Clinical Pharmacy, Division Laboratories, Pharmacy and Biomedical Genetics University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Louise","family":"De Bruin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science Utrecht University  Utrecht The Netherlands"},{"name":"Copenhagen Centre for Regulatory Science, Department of Pharmacy, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"},{"name":"Department of Pharmaceutical Sciences, School of Health Sciences University of Iceland  Reykjavik Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14222"},{"key":"e_1_2_12_3_1","unstructured":"European Medicines Agency.Renin\u2010angiotensin\u2010system (RAS)\u2010acting agents. European Medicines Agency. Published September 17 2018. Accessed August 20 2020.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/renin-angiotensin-system-ras-acting-agents"},{"key":"e_1_2_12_4_1","unstructured":"Overview of the renin\u2010angiotensin system \u2010 UpToDate. Accessed September 1 2020.https:\/\/www.uptodate.com\/contents\/overview-of-the-renin-angiotensin-system?search=renin%20angiotensin%20%20agents&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801317"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303154"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208799"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f360"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4219"},{"issue":"3","key":"e_1_2_12_10_1","first-page":"798","article-title":"Data Resource Profile: The Danish National Prescription Registry","volume":"46","author":"Potteg\u00e5rd A","year":"2017","journal-title":"Int J Epidemiol"},{"key":"e_1_2_12_11_1","unstructured":"Cochrane Effective Practice and Organisation of Care (EPOC).Interrupted time series (ITS) analyses. EPOC Resources for review authors. Published2017. Accessed December 10 2020.http:\/\/epoc.cochrane.org\/resources\/epoc-specific-resources-review-authors"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.12.018"},{"issue":"1","key":"e_1_2_12_13_1","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial","volume":"46","author":"Bernal JL","year":"2017","journal-title":"Int J Epidemiol"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2750"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_2_12_16_1","unstructured":"European Medicines Agency.Trends in co\u2010prescribing of renin\u2010angiotensin system (RAS)\u2010acting agents in France Germany and the UK during 2001\u20102012. ENCePP. Accessed August 23 2020.http:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=33362"},{"key":"e_1_2_12_17_1","unstructured":"BechJN HansenKW BangLE OxlundCS ChristensenKL.HYPERTENSIO ARTERIALIS \u2013 BEHANDLINGSVEJLEDNING 2015 [Treatment guideline]. Published online2015:41."},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht151"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2007.11.008"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03835.x"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1304"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14748"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15080","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15080","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T14:31:09Z","timestamp":1692973869000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/bcp.15080"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15080","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2021,10,8]]}}}